Lydia Dorrego
Directeur Technique/Scientifique/R&D chez Cellerix SA
Profil
Lydia Dorrego is currently the Director of Clinical Operations at Cellerix SA. Previously, she worked as a Principal at GE Healthcare Ltd.
Ms. Dorrego holds a Master's degree in Business Administration from the Instituto Tecnológico y de Estudios Superiores de Monterrey and an undergraduate degree from the Universida de Alcalá de Henares.
Postes actifs de Lydia Dorrego
| Sociétés | Poste | Début |
|---|---|---|
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Directeur Technique/Scientifique/R&D | 25/11/2009 |
Anciens postes connus de Lydia Dorrego
| Sociétés | Poste | Fin |
|---|---|---|
GE Healthcare Ltd. (United Kingdom)
 GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Lydia Dorrego
| Universida de Alcalá de Henares | Undergraduate Degree |
| Instituto Tecnológico y de Estudios Superiores de Monterrey | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
GE Healthcare Ltd. (United Kingdom)
GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Health Technology |